BIO-TECHNE TO PRESENT AT THE BAIRD 2022 GLOBAL HEALTHCARE CONFERENCE
Bio-Techne Corporation (NASDAQ: TECH) announced that CEO Chuck Kummeth will present at the Baird 2022 Global Healthcare Conference on September 14, 2022, at 12:50 p.m. EST. The live webcast will be available on their Investor Relations website. Bio-Techne specializes in high-quality purified proteins, reagents, and genomic tools, generating approximately $1.1 billion in net sales in fiscal 2022. Their extensive product portfolio supports researchers and clinical labs in drug discovery and molecular diagnostics.
- None.
- None.
MINNEAPOLIS, Sept. 6, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Baird 2022 Global Healthcare Conference on Wednesday, September 14, 2022, at 12:50 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, T-Cell activation and gene editing technologies. Bio-Techne's product portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, offering researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment. Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and custom assay development on dedicated clinical instruments. Bio-Techne's genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx® Prostate test for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne's Diagnostics and Genomics Segment. Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately
Contact: | David Clair, Vice President, Investor Relations |
612-656-4416 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-baird-2022-global-healthcare-conference-301616300.html
SOURCE Bio-Techne Corporation
FAQ
When will Bio-Techne present at the Baird 2022 Global Healthcare Conference?
Who will represent Bio-Techne at the conference?
Where can I watch the Bio-Techne presentation live?
What does Bio-Techne specialize in?
What was Bio-Techne's net sales in fiscal 2022?
